NCT06643208View on ClinicalTrials.gov

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

RecruitingOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

March 1, 2027

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

TACE-HAIC, Envafolimab and Lenvatinib

TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib

Trial Locations (1)

Unknown

RECRUITING

Fujian Provincial Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Provincial Hospital

OTHER